Nassif David W. 4
4 · Axovant Gene Therapies Ltd. · Filed Jun 15, 2020
Insider Transaction Report
Form 4
Nassif David W.
Principal Financial Officer
Transactions
- Tax Payment
Common Shares
2020-06-11$3.25/sh−5,266$17,115→ 18,944 total - Disposition to Issuer
Restricted Stock Units
2020-06-12−15,060→ 15,060 total→ Common Shares (15,060 underlying) - Award
Common Shares
2020-06-11+15,060→ 24,210 total
Footnotes (3)
- [F1]Balance includes 9,150 shares of Common Stock owned by the reporting person prior to his appointment as a Section 16 officer but was not previously reported.
- [F2]Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
- [F3]Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted.